Nippon Shinyaku (TSE:4516) has exercised its option with AB2 BIO to secure exclusive United States commercialization rights for Tadekinig alfa, a rare disease therapy with multiple special regulatory designations.
See our latest analysis for Nippon Shinyaku.
The Tadekinig alfa agreement comes as Nippon Shinyaku’s recent 1-day share price return of 1.9% contrasts with a year to date share price decline of 36.05%. The 1-year total shareholder return of 12.02% sits against a 5-year total shareholder return decline of 53.9%, which suggests near term momentum is trying to recover after a weaker multi year experience.
If Tadekinig alfa has you thinking about rare disease and biotech opportunities more broadly, it could be a good moment to scan beyond Nippon Shinyaku and check out 7 healthcare AI stocks
Nippon Shinyaku trades well below both internal fair value estimates and analyst targets, even after the Tadekinig alfa news. Is that a clear discount, or is the market pricing in real execution and earnings risks?
Preferred P/E of 8x for Nippon Shinyaku: Is it justified?
On a P/E of 8x, Nippon Shinyaku looks cheaper than many peers, which raises the question of whether the market is underpricing its earnings power or correctly bracing for pressure ahead.
The P/E ratio compares the current share price with earnings per share and is a common way investors think about how much they are paying for each unit of profit. For a pharmaceutical and biotech company like Nippon Shinyaku, this can reflect expectations around future pipelines, patent cycles and the stability of existing products.
Here, the stock trades at a P/E of 8x while analysts expect earnings to decline on average by 32% per year over the next 3 years and return on equity is forecast at 3.3%. That combination suggests the lower multiple could be the market factoring in weaker profitability rather than ignoring strong prospects. At the same time, the current P/E of 8x sits below the estimated fair P/E of 9.7x. This points to some room for the valuation to move closer to that fair level if the narrative around earnings stabilises.
Compared with the JP Pharmaceuticals industry average P/E of 15.3x and a peer average of 18.8x, Nippon Shinyaku trades at a clear discount. That gap is wide, and the fair P/E estimate of 9.7x still sits above the current level. This frames a potential valuation range the market could gravitate towards if expectations change.
Explore the SWS fair ratio for Nippon Shinyaku
Result: Price-to-earnings of 8x (UNDERVALUED)
However, Nippon Shinyaku still faces risks if earnings continue to decline and key rare disease projects, such as Tadekinig alfa or ATSN-10, fall short of expectations.
Find out about the key risks to this Nippon Shinyaku narrative.
Another View on Nippon Shinyaku’s Valuation
The earlier P/E discussion suggests Nippon Shinyaku looks inexpensive. The SWS DCF model tells a different story. At ¥3,539 the stock trades above an estimated future cash flow value of ¥2,111.01, which signals an overvalued result on this method.
This raises a practical question for investors: should more weight sit with the earnings multiple that compares well against peers, or with a cash flow model that flags limited upside from here?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Nippon Shinyaku for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 18 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
If this combination of caution and potential around Nippon Shinyaku leaves you undecided, take a closer look at both sides of the story and decide for yourself by reviewing the 3 key rewards and 1 important warning sign
Looking for more Nippon Shinyaku investment ideas?
If Nippon Shinyaku has sharpened your focus on valuation and risk, use the Simply Wall St screener to compare it with other opportunities that might fit your style.
Broaden your watchlist with companies that match your objectives and risk comfort, so you are not relying on a single stock story when markets shift.
- Target potential mispricing by reviewing companies that screen as attractively valued through the 18 high quality undervalued stocks.
- Strengthen your income focus with stocks that pair higher yields with resilience using the 43 dividend fortresses.
- Prioritise capital protection and stability by assessing companies that pass the 56 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com